Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Neuroimmunol ; 362: 577761, 2022 01 15.
Article in English | MEDLINE | ID: mdl-34823121

ABSTRACT

A retrospective, observational analysis of 47 patients with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) enrolled at the University of Utah healthcare system was conducted. Visual acuity, neurological disability, and pain medication use were compared in relapsing versus non-relapsing patients. The median observation period was 3.6 years (range: 0.0-11.4 years); the annual relapse rate was 0.1376 (95% confidence interval: 0.0874, 0.191). Relapsing patients (n = 14) exhibited diminished visual acuity, clinically meaningful worsening of neurological disability, and greater pain medication use than non-relapsing patients (n = 33). Therapies that reduce the risk of relapses should be considered when making treatment decisions.


Subject(s)
Cost of Illness , Neuromyelitis Optica , Adult , Aged , Aquaporin 4/immunology , Autoantibodies/immunology , Autoantigens/immunology , Cohort Studies , Disability Evaluation , Female , Humans , Immunoglobulin G , Male , Middle Aged , Neuromyelitis Optica/immunology , Recurrence , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...